Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -78.57%. A quarter ago, it was expected that this company would post a loss of $0.11 per share when it actually produced earnings of $0.04, delivering a surprise of 136.36%.Over the last four quarters, the co ...

Exhibit 99.1 – ARCALYST 2024 expected net product revenue increased to $370 - $390 million – – Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, BERMUDA – April 23, 2024 – Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a commercial-stage biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported first quarter 2024 financial results and recent portfolio execution. "One of the drive ...

– ARCALYST® (rilonacept) Q1 2024 net product revenue of $78.9 million, representing 85% year-over-year growth –– ARCALYST 2024 expected net product revenue increased to $370 - $390 million –– Abiprubart Phase 2b trial in Sjögren's Disease planned to initiate in 2H 2024 –– Current operating plan expected to remain cash flow positive on an annual basis – – Conference call and webcast scheduled for 8:30 am ET today – HAMILTON, Bermuda, April 23, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KN ...

HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:30 a.m. Eastern Time to report its first quarter 2024 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company's website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon re ...

HAMILTON, Bermuda, April 16, 2024 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 23, 2024 at 8:30 a.m. Eastern Time to report its first quarter 2024 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon r ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Table of Contents OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38492 Kiniksa Pharmaceuticals, Ltd. (Exact name of registrant as specified in its charter) Bermuda 98-1327726 (I.R ...

Kiniksa Pharmaceuticals Ltd. (NASDAQ:KNSA) Q4 2023 Earnings Conference Call February 28, 2024 8:30 AM ET Company Participants Rachel Frank - Associate Director of Investor Relations Sanj Patel - Chief Executive Officer Ross Moat - Senior Vice President & Chief Commercial Officer John Paolini - Senior Vice President & Chief Medical Officer Mark Ragosa - Senior Vice President & Chief Financial Officer Conference Call Participants Anupam Rama - JPMorgan Paul Choi - Goldman Sachs Operator Good day and thank you ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) Incorporation or Organization) Identification No.) Kiniksa Pharmaceuticals, Ltd. Clarendon House 2 Church Street Hamilton HM11, Bermuda (808) 451-3453 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transiti ...

| --- | --- | --- | --- | --- | |-------|-------|----------------------------|-------|-------| | | | | | | | | | Third Quarter 2023 | | | | | | | | | | | | Financial Results and | | | | | | Recent Portfolio Execution | | | Agenda 2 This presentation (together with any other statements or information that we may make in connection herewith) contains forward-looking statements with respect to Kiniksa Pharmaceuticals, Ltd. (and its consolidated subsidiaries, collectively, unless context otherwise requires, "Ki ...

Kiniksa Pharmaceuticals Ltd (NASDAQ:KNSA) Q3 2023 Earnings Conference Call October 31, 2023 8:30 AM ET Company Participants Rachel Frank - Associate Director, IR Sanj Patel - CEO Ross Moat - SVP and CCO Mark Ragosa - SVP and CFO John Paolini - SVP and CMO Conference Call Participants Anupam Rama - JPMorgan Paul Choi - Goldman Sachs David Nierengarten - Wedbush Securities Liisa Bayko - Evercore ISI Operator Good day and thank you for standing by. Welcome to the Kiniksa Pharmaceuticals Third Quarter 2023 Earn ...